Method of delivering drug with aid of effervescent activity generated in environment of use

• US 4,265,874 A
• Filed: 04/25/1980
• Issued: 05/05/1981
• Est. Priority Date: 04/25/1980
• Status: Expired due to Term

• Current Assignee: ALZA Corporation (Johnson & Johnson)
• Original Assignee: ALZA Corporation (Johnson & Johnson)
• Inventors: Theeuwes, Felix, Wong, Patrick S., Bonsen, Pieter
• Primary Examiner(s): Rose, Shep K.
• Application Number:
  US06/143,644
• Time in Patent Office: 375 Days
• Field of Search: 424/14, 424/19, 424/22, 424/44, 424/274, 128/260
• US Class Current: 424/473
• CPC Class Codes: A61K 9/0004 Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas

Abstract

A method is disclosed for delivering a drug substantially free of rapid precipitation from an osmotic device. The osmotic device comprises a semipermeable wall surrounding a compartment, housing (1) a drug that exhibits limited solubility under neutral and acid conditions; and (2) a compound capable of evolving carbon dioxide in the presence of an acid in the environment of use. The method comprises, (a) imbibing fluid through the wall into the compartment at a rate determined by the permeability of the wall and the osmotic pressure gradient across the wall, (b) forming in the compartment a basic solution containing drug and compound, which solution is delivered from the compartment through the passageway, (c) reacting the compound with the acid in the environment at the device-environment interface for evolving carbon dioxide, thereby, (d) providing an effervescent suspension in the environment that delivers the drug in a finely dispersed form to the environment of use over time. Also, a composition is disclosed comprising the drug and the compound.

Claims

1. An osmotic device for delivering a drug to an environment of use, said device comprising:

(a) a shaped laminated wall comprising a lamina formed of a semi-permeable material and a lamina formed of a microporous material, said wall permeable to the passage of an external fluid present in the environment of use and substantially impermeable to the passage of drug, the wall surrounding and forming;

(b) a compartment containing the drug indomethacin which exhibits a limited solubility in the fluid, and a pharmaceutically acceptable compound selected from the group consisting of carbonates, bicarbonates and mixtures thereof, which compounds are capable of reactively effervescing with fluid present in the environment of use; and

,

(c) a passageway in the wall connecting the compartment and the exterior of the device for delivering (1) the drug in a therapeutically effective amount to the envirionment, and (2) the compound which reacts with fluid in the environment and effervesces, and thereby aids in delivering the drug to the environment over a prolonged period of time.

2. The osmotic device for delivering the drug according to claim 1 wherein the drug is sodium indomethacin trihydrate.

3. The osmotic device for delivering the drug according to claim 1 wherein the drug is delivered in a therapeutically effective amount of 2 milligrams to 15 milligrams per hour.

4. The osmotic device for delivering the drug according to claim 1 wherein the bicarbonate is potassium bicarbonate.

5. The osmotic device for delivering the drug according to claim 1 wherein the carbonate is potassium carbonate.

6. The osmotic device for delivering the drug according to claim 1 wherein the microporous lamina comprises 45% of cellulose acetate having an acetyl content of 39.8%, 27.5% of hydroxypropyl methylcellulose and 27.5% of polyethylene glycol, and the semipermeable lamina comprises 50% of cellulose acetate having an acetyl content of 39.8%, and 50% of cellulose acetate having an acetyl content of 32%.

7. The osmotic device for delivering the drug according to claim 1 wherein the microporous lamina comprises 45% of cellulose acetate having an acetyl content of 39.8%, 45% of sorbitol, and 10% of polyethylene glycol, and the semipermeable lamina comprises 50% of cellulose acetate having an acetyl content of 39.8%, and 50% of cellulose acetate having an acetyl content of 32%.

8. The osmotic device for delivering the drug according to claim 1, wherein (1) the indomethacin exhibits a limited solubility in the fluid and precipitates therein, and wherein (2) the compound reacts with the fluid in the environment and effervesces, which effervescence substantially prevents precipitation of the drug at the passageway of the device over a prolonged period of time.

9. The osmotic device for delivering the drug according to claim 1 wherein the environment of use is a human, and the device is orally admitted into the gastrointestinal tract.

10. The osmotic device for delivering the drug according to claim 1 wherein, when the device is in operation in the environment of use, fluid therefrom is imbibed through the wall into the compartment in a tendency towards osmotic equilibrium, at a rate determined by the permeability of the wall and the osmotic pressure gradient across the wall to form a solution of compound containing the drug, which solution is delivered through the passageway to the environment of use, with the compound effervescing in the environment, and the drug being delivered to the environment in a therapeutically effective amount over a prolonged period of time.

11. An osmotic device for orally delivering a drug to a human, which device comprises:

(a) a shaped laminated wall comprising a semipermeable lamina and a microporous lamina, said wall permeable to the passage of an external fluid and substantially impermeable to the passage of drug, the wall surrounding and forming;

(b) a compartment containing from 0.5 milligrams to 3 grams of the drug indomethacin, and from 0.5 milligrams to 3 grams of a pharmaceutically acceptable compound selected from the group consisting of carbonates, bicarbonates and mixtures thereof that are capable of effervescing in the presence of the fluid; and

,

(c) a passageway in the wall for delivering from the device at a controlled and continuous rate, a therapeutically effective amount of the drug, and an amount of the compound for reactively effervescing with the fluid over a prolonged period of time.

12. The osmotic device for orally delivering the drug according to claim 11 wherein the device is orally admitted into the gastrointestional tract and the fluid is gastric fluid.

13. The osmotic device for orally delivering the drug according to claim 11 wherein the carbonate is a member selected from the group consisting of lithium carbonate, sodium carbonate, potassium carbonate, ammonium carbonate, magnesium carbonate, calcium carbonate, and mixtures thereof.

14. The osmotic device for orally delivering the drug according to claim 11 wherein the bicarbonate is a member selected from the group consisting of lithium bicarbonate, sodium bicarbonate, potassium bicarbonate, magnesium bicarbonate, calcium bicarbonate, and mixtures thereof.

15. The osmotic device for orally delivering the drug according to claim 11 wherein the indomethacin is sodium indomethacin trihydrate and the compartment contains from 40 milligrams to 250 milligrams of said indomethacin, and the bicarbonate is potassium bicarbonate and the compartment contains from 50 milligrams to 300 millgrams of said bicarbonate.

16. The osmotic device for orally delivering the drug according to claim 11 wherein the indomethacin is sodium indomethacin trihydrate and the compartment contains from 85 milligrams to 125 milligrams thereof, and the bicarbonate is potassium bicarbonate and the compartment contains from 130 milligrams to 190 milligrams thereof.

17. The osmotic device for orally delivering the drug according to claim 11 wherein the indomethacin is sodium indomethacin trihydrate and the compartment contains 105 milligrams thereof, and the bicarbonate is potassium bicarbonate and the compartment contains 142 milligrams thereof.

18. The osmotic device for orally delivering the drug according to claim 11 wherein the indomethacin is sodium indomethacin trihydrate and the compartment contains 105 milligrams thereof, and the bicarbonate is potassium bicarbonate and the comparment contains 158 milligrams thereof.

19. The osmotic device for orally delivering the drug according to claim 11 wherein the microporous lamina comprises cellulose acetate, hydroxypropyl methylcellulose and polyethylene glycol, and the semipermeable lamina comprises cellulose acetate having an acetyl content of 32% and cellulose acetate having an acetyl content of 39.8%.

20. The osmotic device for orally delivering the drug according to claim 11 wherein the microporous lamina comprises cellulose acetate, sorbitol and polyethylene glycol, and the semipermeable lamina comprises cellulose acetate having an acetyl content of 39.8% and cellulose acetate having an acetyl content of 32%.

21. An osmotic device for orally delivering a drug to a human, which device comprises:

(a) a shaped semipermeable, wall said wall permeable to the passage of an external fluid and substantially impermeable to the passage of drug, the semipermeable wall surrounding and forming;

(b) a compartment containing from 0.5 milligrams to 3 grams of the drug indomethacin, and from 0.5 milligrams to 3 grams of a pharmaceutically acceptable compound selected from the group consisting of carbonates, bicarbonates and mixtures thereof that are capable of reactively effervescing in the presence of the fluid; and

,

(c) a passageway in the wall for delivering from the device to the human at a controlled and continuous rate, a therapeutically effective amount of the drug, and an amount of the compound for reactively effervescing with the fluid over a prolonged period of time.

22. The osmotic device for orally delivering the drug according to claim 21 wherein the device is orally admitted into the gastrointestional tract, and the fluid is gastric fluid.

23. The osmotic device for orally delivering the drug according to claim 21 wherein the carbonate is a member selected from the group consisting essentially of lithium carbonate, sodium carbonate, potassium carbonate, ammonium carbonate, magnesium carbonate, calcium carbonate, and mixtures thereof.

24. The osmotic device for orally delivering the drug according to claim 21 wherein the bicarbonate is a member selected from the group consisting of lithium bicarbonate, sodium bicarbonate, potassium bicarbonate, magnesium bicarbonate, calcium bicarbonate, and mixtures thereof.

25. The osmotic device for orally delivering the drug according to claim 21 wherein the indomethacin is sodium indomethacin trihydrate and the compartment contains from 40 milligrams to lb 250 milligrams of said indomethacin, and the bicarbonate is potassium bicarbonate and the compartment contains from 50 milligrams to 300 milligrams of said bicarbonate.

26. The osmotic device for orally delivering the drug according to claim 21 wherein the indomethacin is sodium indomethacin trihydrate and the compartment contains from 85 milligrams to 125 milligrams thereof, and the bicarbonate is potassium bicarbonate and the compartment contains from 130 milligrams to 190 milligrams thereof.

27. The osmotic device for orally delivering the drug according to claim 21 wherein the semipermeable material comprises a selectively permeable polymer selected from the group consisting of cellulose acylate, cellulose diacylate, cellulose triacylate, cellulose acetate, cellulose diacetate, cellulose triacetate, and mixtures thereof.

28. The osmotic device for orally delivering the drug according to claim 21 wherein the semipermeable wall comprises cellulose acetate having an acetyl content of 32% and cellulose acetate having an acetyl content of 39.8%.

29. The osmotic device for orally delivering a drug according to claim 21 wherein semipermeable wall comprises 50% of cellulose acetate having an acetyl content of 32%, and 50% of cellulose acetate having an acetyl content of 39.8%.